 |
Trials |
A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies and Metastatic Breast CancerCancer type: Ovarian cancer Phase: II Principal Investigator: Juhler-Nøttrup Trine Country: DK Keywords: Denmark, Herlev, karyopharm, KPT-330, selinexor, SIGN, ovarian cancer, endometrial cancer, cervical cancer, SINE, breast cancer, HER2 negative Status: Completed Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02025985?term=02025985&rank=1 |